Research Support Centre
Technology Platforms

Protein Crystallography by Experimental Drug Development Centre (EDDC)


SMYD3 structure solved by XRAY


Understanding protein-ligand interactions is pivotal for accelerating lead identification and structure guided lead optimisation. Our team of experts at the X-ray crystallography (XRAY) platform support the determination of high-resolution structures of proteins and ligand binding conformations. 

The X-ray team provides a customised approach to your structural characterization studies starting from protein expression & purification to optimization of crystallization conditions to generate atomic resolution structures using commercial Beam line at Australian synchrotron & Japan Spring-8 synchrotron.


Key Services 

  • Highly purified protein for biophysical studies
  • Consultation for X-ray structure solution
  • Access to industrial Beam time and assisting in data collection 


EYA2 structure solved by XRAY


 PYCR structure solved by XRAY


Key Capabilities

  • Expertise in co-crystallization for Drug Discovery
  • Validation of small molecule scaffold engagement
  • Protein-Protein interactions
  • Ligand-Protein interactions 
  • Peptide-Protein interactions


Expertise in Diverse Targets 

  • Methytransferases
  • Decarboxylase
  • PKinase/Atypical Kinase
  • Transcription factor
  • Phosphatase
  • Protease
  • Reductase
  • Mitochondrial fission  


 EYA2 structure solved by XRAY



Protein Structure & Biophysics consisting of Fragment Based Screening (FBS) and Protein crystallography (XRAY) is part of the EDDC Academic Research Organisation or EARO, a Fee-for-Service initiative by the Experimental Drug Development Centre (EDDC). Founded in 2020, EARO was conceived to provide greater access to EDDC’s rich scientific expertise and state of the art technology platforms to the academic and industry researchers in the biomedical ecosystem who aspire to embark on a journey of translating their research into drug candidates. EARO comprises primarily of 5 core drug discovery platforms headed by scientists with decades of experience.  The EARO Platforms include High Throughput Screening (HTS), Fragment Based Screening (FBS), Protein Crystallography (XRAY), High Throughput Phenomics (HTP) and Computational Phenomics Platforms (CPP). Together, EARO groups have engaged with more than 70 academic and industry partners.

Visit for more information  or email